Cramlington-headquartered pharmaceutical development and manufacturing company, Sterling Pharma Solutions, has announced its acquisition of a facility in Germantown, Wisconsin, US.
The facility will further bolster the company’s US presence and will allow Sterling to continue to meet growing customer demand in the US and further afield, as well as support the increase in export demand for its services.
The acquisition follows Sterling’s sustained growth over the past four years, which has seen the company invest over £35million into its service offering globally, including a recent £11m investment into a new milling and solid form facility at the UK headquarters, which opened earlier this month.
Firmly established in the North East since 1969 the company continues to invest in its headquarters and is regularly recruiting in the region. Over the last three years Sterling has added over 200 employees at it Cramlington facility.
Commenting on the announcement, Kevin Cook, CEO of Sterling Pharma Solutions, said:
“We’re delighted to announce the acquisition of a second facility in the US. This is the latest step of our strategic growth plans and will ensure we continue to provide a strong offering to our global customer base.
“The site’s capabilities complement our current service offering and will allow us to continue to provide first-class service to our customers.
“We remain committed to the North-East and will continue to invest in our headquarters in Cramlington, as well as explore future opportunities to meet our ambitious growth targets.
“We’re excited to welcome the Germantown team into the Sterling family.”
The US facility is being purchased from another pharmaceutical development and manufacturing company called Alcami. Sterling Pharma Solutions went through an MBO in 2016 and has seen 25% growth year-on-year.
The company, which now employs over 700 people, is a global contract development and manufacturing organisation (CDMO) and is one of the largest providers of small molecule active pharmaceutical ingredient (API) development and manufacturing services to the pharmaceutical industry, specialising in handling challenging chemistries.
With over 50 years’ experience, the team can manage the most complex API challenges from proof-of-concept to commercial manufacture.
In addition to the new Germantown facility Sterling and its HQ in Dudley, Northumberland, UK, the company also has laboratories and scale up facilities in Cary, North Carolina, US.